Ron Mathijssen

Ron Mathijssen is a Full Professor in the Department of Medical Oncology at Erasmus MC, Erasmus School of Medicine. His work bridges clinical oncology and pharmacology, focusing on optimizing cancer drug therapies through pharmacokinetic and pharmacodynamic insights.

• Institution: Erasmus MC
• School: Erasmus School of Medicine
• Department: Medical Oncology
• Academic Rank: Professor

His primary research interests lie in pharmacokinetics, therapeutic drug monitoring, personalized chemotherapy, and clinical pharmacology in oncology. He investigates how individual patient factors affect drug response, particularly for agents like irinotecan, docetaxel, paclitaxel, and fluoropyrimidines.

The recent publications highlight a strong trend toward precision oncology and individualized dosing strategies. His work integrates pharmacogenomics (e.g., DPYD), serum biomarkers (e.g., uracil), and pharmacokinetic modeling to tailor treatments and reduce adverse effects. There is a growing focus on immune checkpoint inhibitors and their complications, as well as novel delivery methods like intraperitoneal chemotherapy.

While no specific awards are listed in the provided text, his leadership in multicenter clinical trials and high-volume publication record in top journals indicates significant recognition in the oncology and pharmacology communities.

Dr. Mathijssen has supervised 31 research works, reflecting an active role in mentoring the next generation of clinical researchers. He is involved in major studies such as the Alpe2U trial and PROACTIVE-B, which are designed to improve drug safety and efficacy through pharmacological optimization. His research is supported by collaborative networks across Europe, particularly in the domain of cancer pharmacology.

He is part of a robust research team at Erasmus MC focused on clinical pharmacology in oncology, likely contributing to a larger lab or research group that integrates translational research with patient care. His work is highly collaborative, involving multidisciplinary teams including pharmacologists, oncologists, and clinical trial specialists.